antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2023-68-3-4-25-29antibiotics-1015Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSIn vitro и in vivo иммуноадъювантные эффекты модифицированного ферментативным гидролизом фукоиданаIn vitro and in vivo Immunoadjuvant Effects of the Enzymatically Modified Fucoidanhttps://orcid.org/0000-0002-4315-6959КузнецоваТ. А.KuznetsovaT. A.

Кузнецова Татьяна Алексеевна — д. м. н., главный научный сотрудник лаборатории иммунобиологических препаратов

ResearcherID: I-8399-2018. eLIBRARY SPIN-код: 2359-1132. Scopus Author ID: 7202571979

ул. Сельская, д. 1, г. Владивосток, 690087.

Tatiana A. Kuznetsova — D. Sc. in Medicine, Chief researcher of Immunobiological preparations

ResearcherID: I-8399-2018. eLIBRARY SPIN-код: 2359-1132. Scopus Author ID: 7202571979

1 Selskaya st., Vladivostok, 690087

takuznets@mail.ruhttps://orcid.org/0000-0003-4505-3627СмолинаТ. П.SmolinaT. A.

Смолина Татьяна Павловна — к. б. н., ведущий научный сотрудник лаборатории иммунобиологических препаратов

ResearcherID: J-4344-2018. eLIBRARY SPIN-код: 3503-8898. Scopus Author ID: 6603763859

Владивосток

Tatiana P. Smolina — Ph. D. in Biology, Leading researcher of Immunobiological preparations

ResearcherID: J-4344-2018. eLIBRARY SPIN-код: 3503-8898. Scopus Author ID: 6603763859

Vladivostok

https://orcid.org/0000-0001-9525-668XИванушкоЛ. А.IvanushkoL. A.

Иванушко Людмила Александровна — к. м. н., старший научный сотрудник лаборатории иммунологии

ResearcherID: K-2879-2018. eLIBRARY SPIN-код: 1535-7665. Scopus Author ID: 6507058048

Владивосток

Lyudmila A. Ivanushko — Ph. D. in Medicine, Senior Researcher of Immunobiological preparations

ResearcherID: K-2879-2018. eLIBRARY SPIN-код: 1535-7665. Scopus Author ID: 6507058048

Vladivostok

https://orcid.org/0000-0002-5686-8672ПерсияноваЕ. В.PersiyanovaE. V.

Персиянова Елена Викторовна — к. б. н., старший научный сотрудник лаборатории иммунологии

ResearcherID: I-3513-2018. eLIBRARY SPIN-код: 8385-7621. Scopus Author ID: 56311963200

Владивосток

Elena V. Persiyanova — Ph. D. n Biology, Senior Researcher of Immunobiological preparations

ResearcherID: I-3513-2018. eLIBRARY SPIN-код: 8385-7621. Scopus Author ID: 56311963200

Vladivostok

https://orcid.org/0000-0002-3502-5692СильченкоА. С.SilchenkoA. S.

Сильченко Артем Сергеевич — к. х. н., старший научный сотрудник лаборатории химии ферментов

ResearcherID: M-6894-2013. eLIBRARY SPIN-код: 4416-4006. Scopus Author ID: 6701513689

Владивосток

Artem S. Silchenko — Ph. D. in Chemistry, Senior researcher of Laboratories of enzyme chemistry

ResearcherID: M-6894-2013. eLIBRARY SPIN-код: 4416-4006. Scopus Author ID: 6701513689

Vladivostok

https://orcid.org/0000-0002-2760-9778БеседноваН. Н.BesednovaN. N.

Беседнова Наталия Николаевна — д. м. н., профессор, Академик РАН, главный научный сотрудник лаборатории иммунологии

eLIBRARY SPIN-код: 8931-9002. Scopus Author ID: 7006805123

Владивосток

Natalia N. Besednova — D. Sc. in Medicine, Professor, Academician of the Russian Academy of Sciences, Chief Researcher at the Laboratory of Immunology

eLIBRARY SPIN-код: 8931-9002. Scopus Author ID: 7006805123

Vladivostok

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова», РоспотребнадзораРоссияG. P. Somov Research Institute of Epidemiology and MicrobiologyRussian FederationТихоокеанский институт биоорганической химии им. Г. Б. Елякова ДВО РАНРоссияG. B. Elyakov Pacific Institute of Bioorganic ChemistryRussian Federation202318072023683-42529Copyright © Кузнецова Т.А., Смолина Т.П., Иванушко Л.А., Персиянова Е.В., Сильченко А.С., Беседнова Н.Н., 20232023Кузнецова Т.А., Смолина Т.П., Иванушко Л.А., Персиянова Е.В., Сильченко А.С., Беседнова Н.Н.Kuznetsova T.A., Smolina T.A., Ivanushko L.A., Persiyanova E.V., Silchenko A.S., Besednova N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1015

Цель. Сравнительное изучение иммуноадъювантной активности фукоиданов из бурой водоросли Fucus evanescens (образцы 1 и 2) в отношении овальбумина (ОВА) in vitro и in vivo. Материал и методы. Образец 1 — модифицированный ферментативным гидролизом фукоидан, образец 2 — нативный фукоидан. Влияние фукоиданов in vitro на уровень экспрессии основных иммунофенотипических маркеров клеток врождённого и адаптивного иммунитета (нейтрофилов, натуральных киллеров, моноцитов, лимфоцитов) исследовали методом проточной цитометрии. Иммуноадъювантные эффекты фукоидана in vivo оценивали по продукции сывороточных антител (IgG, IgG1, IgG2а) и цитокинов (IFNγ, IL-2, IL-10, IL-12) у мышей BALB/c, иммунизированных ОВА. Результаты. Исследованные образцы фукоидана активировали эффекторные функции клеток врождённого и адаптивного иммунитета in vitro и усиливали Th1 (IgG2а, INFγ, IL-2) и Th2 (IgG1, IL-10) иммунный ответ к ОВА in vivo. Выводы. Иммуноадъювантные эффекты модифицированного ферментативным гидролизом фукоидана сопоставимы с таковыми нативного фукоидана.

Objectives. No sulfated polysaccharides (fucoidans) has been declared as the pharmaceutical substances, adjuvants, etc., which is associated with the problems of obtaining the structurally characterized and homogeneous samples or their oligomeric fractions that retain high biological activity. The highly purified fucoidan with regular reproducible structural characteristics (F1) was obtained by enzymatic hydrolysis of native fucoidan (F2). Aim. The comparative study of fucoidans from the brown alga Fucus evanescens (F1 and F2) effects on the effector functions of innate and adaptive immunity cells loaded with ovalbumin (OVA) in vitro and in vivo. Material and methods. Fucoidan F1 — the enzymatically modified product of native fucoidan; F2 — the native fucoidan. The fucoidans effects on the expression level of the main immunophenotypic markers of innate and adaptive immunity (neutrophils, monocytes, natural killers, lymphocytes) cells in vitro were studied by methods of flow cytometry. The fucoidans effects on the production of serum OVA-specific antibodies (IgG, IgG1, IgG2а) and cytokines (IFNγ, IL-2, IL-10, IL-12) were detected in BALB/c mice immunized with OVA. Results. The tested fucoidans activate the effector functions of innate and adaptive immunity cells loaded with OVA in vitro and act as adjuvants, stimulating both Th1 (IgG2а, INFγ, IL-2) and Th2 (IgG1, IL-10) immune response to OVA in vivo. Conclusions. The immunoadjuvant effect of the enzymatically modified fucoidan (F1) on effector functions of innate and adaptive immunity cells are comparable to those of the native fucoidan (F2). The findings determine the possibility of F1 use as an adjuvant for a wide range of prophylactic and therapeutic vaccines.

фукоиданыадъювантывакциныовальбуминврождённый и адаптивный иммунитетfucoidansadjuvantsvaccinesovalbumininnate and adaptive immunityReferencesAlekseyenko T.V., Zhanayeva S.Y., Venediktova A.A., Zvyagintseva T.N., Kuznetsova T.A., Besednova N.N., Korolenko T.A. Antitumor and antimetastatic activity of fucoidan, a sulfated polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga. Bull Exp Biol Med. 2007; 143 (6): 730–732. doi: 10.1007/s10517-007-0226-4.Alekseyenko T.V., Zhanayeva S.Y., Venediktova A.A., Zvyagintseva T.N., Kuznetsova T.A., Besednova N.N., Korolenko T.A. Antitumor and antimetastatic activity of fucoidan, a sulfated polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga. Bull Exp Biol Med. 2007; 143 (6): 730–732. doi: 10.1007/s10517-007-0226-4.Anastyuk S.D., Shevchenko N.M., Ermakova S.P., Vishchuk O.S., Nazarenko E.L., Dmitrenok P.S., Zvyagintseva T.N. Anticancer activity in vitro of a fucoidan from the brown alga Fucus evanescens and its low-molecular fragments, structurally characterized by tandem mass-spectrometry. Carbohydr Polym. 2012; 87 (1): 186–194. https://doi.org/10.1016/j.carbpol.2011.07.036.Anastyuk S.D., Shevchenko N.M., Ermakova S.P., Vishchuk O.S., Nazarenko E.L., Dmitrenok P.S., Zvyagintseva T.N. Anticancer activity in vitro of a fucoidan from the brown alga Fucus evanescens and its low-molecular fragments, structurally characterized by tandem mass-spectrometry. Carbohydr Polym. 2012; 87 (1): 186–194. https://doi.org/10.1016/j.carbpol.2011.07.036.Menshova R.V., Shevchenko N.M., Imbs T.I., Zvyagintseva T.N., Malyarenko O.S., Zaporoshets T.S., Besednova N.N., Ermakova S.P. Fucoidans from brown alga Fucus evanescens: structure and biological activity. Front Marine Sci. 2016; 3: 1–9. doi: 10.1177/1934578X1801300837.Menshova R.V., Shevchenko N.M., Imbs T.I., Zvyagintseva T.N., Malyarenko O.S., Zaporoshets T.S., Besednova N.N., Ermakova S.P. Fucoidans from brown alga Fucus evanescens: structure and biological activity. Front Marine Sci. 2016; 3: 1–9. doi: 10.1177/1934578X1801300837.Запорожец Т. С., Крыжановский С. П., Персиянова Е. В., Кузнецова Т. А., Смолина Т. П., Гажа А. К., Шевченко Н. М., Звягинцева Т. Н., Ермакова С. П., Беседнова Н. Н. Корригирующее действие фукоидана, сульфатированного полисахарида из бурой водоросли Fucus evanescens, при формировании специфического иммунного ответа против вирусов сезонного гриппа у пожилых людей. Антибиотики и химиотер. 2020; 65 (3–4): 23–28. https://doi.org/10.37489/0235-2990-2020-65-3-4-23–28.Zaporozhets T.S., Kryzhanovsky S.P., Persianova E.V., Kuznetsova T.A., Smolina T.P., Gazha A.K., Shevchenko N.M., Ermakova S.P., Zvyagintseva T.N., Besednova N.N. The corrective effect of fucoidan, a sulfated polysaccharide extracted from brown algae Fucus evanescens, in the formation of a specific immune response against seasonal influenza viruses in the elderly. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2020; 65 (3–4): 23–28. https://doi.org/10.37489/0235-2990-2020-65-3-4-23-28.Silchenko A.S., Rasin A.B., Kusaykin M.I., Malyarenko O.S., Shevchenko N.M., Zueva A.O., Kalinovsky A.I., Zvyagintseva T.N., Ermakova S.P. Modification of native fucoidan from Fucus evanescens by recombinant fucoidanase from marine bacteria Formosa algae. Carbohydr Polym. 2018; 193: 189–195. doi: 10.1016/j.carbpol.2018.03.094.Silchenko A.S., Rasin A.B., Kusaykin M.I., Malyarenko O.S., Shevchenko N.M., Zueva A.O., Kalinovsky A.I., Zvyagintseva T.N., Ermakova S.P. Modification of native fucoidan from Fucus evanescens by recombinant fucoidanase from marine bacteria Formosa algae. Carbohydr Polym. 2018; 193: 189–195. doi: 10.1016/j.carbpol.2018.03.094.Anastyuk S.D., Shevchenko N.M., Dmitrenok P.S., Zvyagintseva T.N. Structural simi-larities of fucoidans from brown algae Silvetia babingtonii and Fucus evanescens, determined by tandem MALDI-TOF mass spectrometry. Carbohydr Res. 2012; 358: 78–81. doi: 10.1016/j.carres.2012.06.015.Anastyuk S.D., Shevchenko N.M., Dmitrenok P.S., Zvyagintseva T.N. Structural simi-larities of fucoidans from brown algae Silvetia babingtonii and Fucus evanescens, determined by tandem MALDI-TOF mass spectrometry. Carbohydr Res. 2012; 358: 78–81. doi: 10.1016/j.carres.2012.06.015.Ikewaki N., Iwasaki M., Kurosawa G., Rao K.-S., Lakey-Beitia J., Preethy S., Abraham S.J.K. β glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B VACCIEN) in specific immunocompromised populations. Hum Vaccin Immunother. 2021; 17 (8): 2808–2813. https://doi.org/10.3892/or.2021.8225.Ikewaki N., Iwasaki M., Kurosawa G., Rao K.-S., Lakey-Beitia J., Preethy S., Abraham S.J.K. β glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B VACCIEN) in specific immunocompromised populations. Hum Vaccin Immunother. 2021; 17 (8): 2808–2813. https://doi.org/10.3892/or.2021.8225.Kim S.-Y., Joo H.-G. Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy. J Vet Sci. 2015; 16 (2): 145–150. doi: 10.4142/jvs.2015.16.2.145.Kim S.-Y., Joo H.-G. Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy. J Vet Sci. 2015; 16 (2): 145–150. doi: 10.4142/jvs.2015.16.2.145.Kuznetsova T.A., Persiyanova E.V., Ermakova S.P., Khotimchenko M.Yu., Besednova N.N. The sulfated polysaccharides of brown algae and products of their enzymatic transformation as potential vaccine adjuvants. Nat Prod Com. 2018; 13 (8): 1083–1095. doi: 10.1177/1934578X1801300837.Kuznetsova T.A., Persiyanova E.V., Ermakova S.P., Khotimchenko M.Yu., Besednova N.N. The sulfated polysaccharides of brown algae and products of their enzymatic transformation as potential vaccine adjuvants. Nat Prod Com. 2018; 13 (8): 1083–1095. doi: 10.1177/1934578X1801300837.Pifferi C., Fuentes R., Fernández-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021; 5: 197–216. doi: 10.1038/s41570-020-00244-3.Pifferi C., Fuentes R., Fernández-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021; 5: 197–216. doi: 10.1038/s41570-020-00244-3.Zhang W., Oda T., Yu Q., Jin J.O. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs. 2015; 13: 1084–1104. doi: 10.3390/md13031084.Zhang W., Oda T., Yu Q., Jin J.O. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs. 2015; 13: 1084–1104. doi: 10.3390/md13031084.Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000; 406:793–798. doi: 10.1038/s41570-020-00244-3.Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000; 406:793–798. doi: 10.1038/s41570-020-00244-3.Coffman R.L, Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33 (4): 492–503. doi: 10.1016/j.immuni.2010.10.002.Coffman R.L, Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33 (4): 492–503. doi: 10.1016/j.immuni.2010.10.002.McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27: 687–690. doi: 10.1016/j.immuni.2007.11.003.McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27: 687–690. doi: 10.1016/j.immuni.2007.11.003.Mathers A.R., Cuff C.F. Role of Interleukin-4 (IL-4) and IL-10 in serum immunoglobulin G antibody responses following mucosal or systemic reovirus. Infect J Virol. 2004; 78: 3352–3360. doi: 10.1128/jvi.78.7.3352-3360.2004.Mathers A.R., Cuff C.F. Role of Interleukin-4 (IL-4) and IL-10 in serum immunoglobulin G antibody responses following mucosal or systemic reovirus. Infect J Virol. 2004; 78: 3352–3360. doi: 10.1128/jvi.78.7.3352-3360.2004.Gherardi R.K., Eidi H., Crepeaux G., Authier F.J., Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015; 6: 4. doi: 10.3389/fneur.2015.00004.Gherardi R.K., Eidi H., Crepeaux G., Authier F.J., Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015; 6: 4. doi: 10.3389/fneur.2015.00004.

The authors declare that there are no conflicts of interest present.